A
TRML

AlphaQuest’s Tourmaline Bio TRML Stock Holding History

AlphaQuest’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,323
Closed -$350K – 2297
2025
Q3 		$350K Buy
7,323
+5,001
+215% +$139K 0.02% 1055
2025
Q2 		$37.1K Sell
2,322
-430
-16% -$6.97K ﹤0.01% 1675
2025
Q1 		$41.9K Sell
2,752
-866
-24% -$13.9K ﹤0.01% 1562
2024
Q4 		$73.4K Sell
3,618
-5,763
-61% -$145K 0.01% 1193
2024
Q3 		$241K Buy
9,381
+5,559
+145% +$92.8K 0.02% 985
2024
Q2 		$49.2K Buy
3,822
+2,189
+134% +$35.2K 0.01% 1071
2024
Q1 		$37.4K Buy
+1,633
New +$57.6K 0.01% 969

AlphaQuest's TRML Position: Q4 2025 in Review

AlphaQuest sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 7,323 shares — an estimated $350K sold.

AlphaQuest first reported a position in TRML in Q1 2024 and held it in 7 quarters. The position peaked at $350K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

  • AlphaQuest reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
  • AlphaQuest sold 7,323 Tourmaline Bio shares in Q4 2025, an estimated $350K.
  • AlphaQuest first reported a position in Tourmaline Bio in Q1 2024 and held it in 7 quarters.
  • AlphaQuest's Tourmaline Bio position peaked at $350K in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on AlphaQuest's 13F filing for Q4 2025, filed 9 Feb 2026.